ACT Patient Selection: Who Is a Good Candidate and Who Is Not | ALIV

Medically Reviewed by Dr. Sunita Tandulwadkar | Written by ALIV

One of ALIV's most important clinical commitments is that ACT is not offered to everyone who wants it — it is recommended only to patients for whom the clinical evidence and individual profile suggest meaningful benefit is achievable. This honest patient selection is not a commercial limitation; it is the clinical foundation of trustworthy regenerative medicine. A therapy offered indiscriminately to any willing patient, regardless of their suitability, produces poor outcomes and damages the credibility of the entire field. Understanding what makes a good ACT candidate helps patients engage with the pre-ACT consultation productively and set appropriate expectations from the outset.

The Ideal ACT Candidate Profile

The patient profile that benefits most from ACT at ALIV shares several characteristics. First, they have a condition for which ALIV's ACT protocol has clinical evidence and mechanism plausibility — the conditions listed in ALIV's programme (osteoarthritis, rheumatoid arthritis, Parkinson's, Alzheimer's, diabetes complications, liver disease, COPD, Crohn's disease, infertility, stroke rehabilitation, restorative anti-ageing) have been selected because the mechanistic rationale for paracrine regenerative support is strongest. Patients with conditions outside this list may not be appropriate candidates.

Second, the ideal candidate has a condition at a stage where meaningful regenerative response is still possible. ACT works by amplifying the body's own repair capacity — which requires that some residual tissue capacity for regeneration exists. For a knee joint with moderate osteoarthritis, meaningful cartilage matrix support and anti-inflammatory modulation are achievable. For a knee with end-stage osteoarthritis and bone-on-bone contact, the regenerative capacity of the remaining tissue is severely limited and ACT cannot produce outcomes comparable to earlier-stage intervention. The same principle applies across conditions: moderate stage generally responds better than end stage.

Third, the ideal candidate is committed to optimising the context in which ACT works — not just receiving the procedure and returning to unchanged habits. ACT outcomes are significantly better in patients who simultaneously optimise sleep, nutrition, activity level, and other contributors to the regenerative environment. ALIV's ACT team provides guidance on these contextual factors as part of the protocol. See: ACT pre-procedure preparation.

Who Is Not an Appropriate ACT Candidate

Absolute exclusions: active malignancy (cancer) — growth factor delivery in the context of active cancer carries unacceptable risk of tumour stimulation; active systemic infection or sepsis; severe coagulopathy making harvest procedures unsafe; pregnancy; and severe organ failure incompatible with recovery from the harvest procedure. Relative exclusions requiring careful individual assessment: significant immunosuppressive therapy for transplant or autoimmune disease (which may affect the ACT biological response); very advanced stage of the target condition where tissue regenerative capacity is exhausted; and patient expectation of cure rather than meaningful improvement (ACT cannot and should not be offered to patients whose expectations cannot be aligned with the evidence-based realistic outcomes).

Is age a limiting factor for ACT?

Age alone is not an exclusion criterion. Older patients have been treated with ACT successfully across ALIV's programme. The relevant consideration is biological age and overall health status rather than chronological age — a 70-year-old with good baseline health, adequate nutritional status, and a well-defined indication may be a better ACT candidate than a 50-year-old with significant comorbidities. Frailty assessment rather than age cutoff is the appropriate clinical approach.

Many ALIV ACT patients come at a point of therapeutic plateau — having tried appropriate conventional management without achieving satisfactory outcomes. This is a valid clinical context for considering ACT. The important distinction is between "exhausted conventional options and seeking additional support" (appropriate) and "hoping ACT will succeed where everything else failed without being willing to engage with the other aspects of management that support it" (unlikely to produce meaningful results). The pre-ACT consultation identifies where each patient sits on this spectrum.

How do I know if my condition is at the right stage for ACT?

Staging assessment is part of the pre-ACT clinical evaluation. For joint conditions, recent imaging (X-ray or MRI) is reviewed to assess cartilage status. For neurological conditions, recent clinical assessment and investigations are reviewed to characterise disease stage. For metabolic and systemic conditions, recent blood markers are reviewed. Where current investigations are not available, ALIV may request specific assessments before confirming candidacy. Patients should bring all relevant recent investigations to their pre-ACT consultation — this allows the most efficient and complete assessment.

Medically Reviewed by Dr. Sunita Tandulwadkar. This article is for informational purposes only and does not constitute medical advice. Therapies offered by ALIV are proprietary, experimental protocols and results vary by individual.